Fusion Antibodies (LON:FAB) Stock Price Up 8.3%

Shares of Fusion Antibodies plc (LON:FAB) were up 8.3% on Tuesday . The stock traded as high as GBX 3.75 ($0.05) and last traded at GBX 3.52 ($0.05). Approximately 432,436 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 994,814 shares. The stock had previously closed at GBX 3.25 ($0.04).

Fusion Antibodies Price Performance

The firm has a 50-day simple moving average of GBX 3.30 and a 200 day simple moving average of GBX 3.48. The firm has a market cap of £3.60 million, a PE ratio of -81.25 and a beta of 0.48. The company has a debt-to-equity ratio of 2.40, a current ratio of 3.87 and a quick ratio of 2.36.

Insider Transactions at Fusion Antibodies

In related news, insider Adrian Kinkaid bought 120,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average cost of GBX 3 ($0.04) per share, with a total value of £3,600 ($4,805.13). In other Fusion Antibodies news, insider Adrian Kinkaid purchased 120,000 shares of the stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average cost of GBX 3 ($0.04) per share, with a total value of £3,600 ($4,805.13). Also, insider Richard John Buick purchased 94,825 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were bought at an average cost of GBX 3 ($0.04) per share, for a total transaction of £2,844.75 ($3,797.05). Insiders have purchased a total of 364,825 shares of company stock valued at $1,094,475 in the last ninety days. 11.50% of the stock is currently owned by corporate insiders.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.